Trial · NCT03703271
Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
NCT03703271, Phase 2, Recruiting, Women's Hospital School Of Medicine Zhejiang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia. Trials, record NCT03703271. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03703271
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
- NCT number
- NCT03703271
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Women's Hospital School Of Medicine Zhejiang University
- Conditions
- Gestational Trophoblastic Neoplasia
- Interventions
- Methotrexate, hysteroscopic repeat curettage
- First posted
- 2018-10-11
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The ultimate complete response rate | 2 years | The investigators may calculate the ultimate complete response rate, defined as the proportion of patients who achieve sustained normalisation of serum hCG without requiring escalation to multi-agent chemotherapy at the predefined trial endpoint. |
| Secondary | chemotherapy-sparing rate | 2 years | The investigators may calculate the rate of response after the initial treatment of hysteroscopic repeat curettage without chemotherapy |
| Secondary | Complications of hysteroscopic repeat curettage surgery | 2 years | The investigators may record the complications of hysteroscopic repeat curettage surgery |
| Secondary | Severity of adverse events as assessed by the WHO | 2 years | The investigators may record the adverse events of chemotherapy as assessed by the WHO |
| Secondary | Overall Survival Rate (OR) | 2 years | Overall Survival Rate of the two group patients |
| Secondary | Ovarian functional evaluation | 2 years | The investigators may test serum level of anti-mullerian hormone (AMH) every 6 months. |
| Secondary | The pregnancy rate | 2 years | To calculate the pregnancy rate in an actuarial manner using the Kaplan-Meier method at the end of the trail |
| Secondary | Menstrual cycle resuming rate | 2 years | The investigators record the time of menstrual cycle resuming after chemotherapy |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03703271
GET https://conductscience.org/api/trials/v1/NCT03703271/registered